Menu DZIAŁALNOŚĆ Oferta Historia i misja Zaufali nam PUBLIKACJE Konferencje, Kongresy i Szkolenia Napisali o nas REKRUTACJA DO BADAŃ Badania Kliniczne Rekrutacja do badań klinicznych Rekrutacja do aktualnie prowadzonych badań PAES/PASS/DUS i innych badań nieinterwencyjnych Kariera Kontakt PUBLIKACJE Na podstawie wyników badań prowadzonych przez Europharma powstały liczne raporty i prace naukowe opublikowane w indeksowanych czasopismach zagranicznych i polskich, dostępne m.in. na MEDLINE, PubMed i innych portalach naukowych. Evaluation of the Safety Profile of Zolafren®, a Generic Olanzapine Formulation, in Patients with Bipolar Disorder: A Post-Authorization Safety Study, Advances in Therapy, DOI 10.1007/s12325-015-0210-8. Link do publikacji : http://www.advancesintherapy.com/Article/21cd5a6a-f42b-45e5-928d-a099aff... Inne z naszych publikacji : Resistant hypertension in visceral obesity, European Journal of Internal Medicine 23 (2012) 643-648. http://www.sciencedirect.com/science/article/pii/S0953620512001197?np=y Quality of life (QOL) evaluation after coronary syndrome with simultaneous clopidogrel treatment, Archives of Medical Science 2014 Feb 24; 10(1): 33-38. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953969/ Depressive symptoms in patients diagnosed with benign prostatic hyperplasia, International Urology and Nephrology 2015; 47(3): 431-440. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341023/ Safety and Tolerance of generic rosuvastatin formulation ( Suvardio®) in therapy of patients with primary hypercholesterolemia and mixed dyslipidemia- results of post-marketing , non-randomized, non-interventional, multicenter survey in outpatient treatment, Problemy Medycyny Rodzinnej 2012.Vol. XV, No.4 http://www.lekarzrodzinny.org/pmr/13213.pdf The adherence and illness perception of patients diagnosed with asthma or chronic obstructive pulmonary disease treated with polytherapy using new generation Cyclohaler, Advances in Dermatology and Allergology 2014 Aug; 31(4): 235-246. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171677/ Safety and tolerance of Plavocorin®, a generic clopidogrel formulation in therapy of patients after acute coronary syndrome- results of a post-marketing, non-randomized, non-interventional, multicenter survey in outpatient treatment, Problemy Medycyny Rodzinnej 2013,VOL.XIV,Nr4 (40) http://www.lekarzrodzinny.org/pmr/160413.pdf Compliance with compression stockings in patients with chronic venous disorders, Phlebology 2011; 26:353-360. Blood pressure for optimal health-related quality of life in hypertensive patients, Journal of Hypertension 2013, 31:000-000. Education using SMS increases efficacy of treatment of hypertensive patients, Arterial Hypertension 2009, vol. 13, no 3, pages 147-157. https://www.google.pl/webhp?hl=pl#hl=pl&q=Education+using+SMS+increases+.... The level of health education in the Polish population, Annals of Agricultural and Environmental Medicine 2013, Vol 20, No 3, 559-565. http://aaem.pl/abstracted.php?level=5&ICID=1067440 Effects of angiotensin-converting enzyme inhibitors lowering blood pressure – are they important for doctors?, Pharmacological Reports 2011, 63, 740-751. http://www.sciencedirect.com/science/article/pii/S1734114011705862 Factors that favor the occurrence of cough in patients treated with ramipril – A pharmacoepidemiological study, Med Sci Monit, 2012; 18(9): Pl21-28. Safety an tolerance of generic levetiracetam formulation (Vetira®) in Polish patients diagnosed with epilepsy – results of a post-marketing, non-randomized, non-interventional, multicenter survey in outpatient practice, Review of Clinical Neuropsychiatry VOL. 5 (NR 3)/2013: 00. http://www.neuropsychiatria.net/37-archiwum/vol-5-nr-3-2013/232-ocena-pr... Analysis of Clinical Symptoms and Laboratory Profiles in Children with Juvenile Idiopathic Arthritis in Malopolska Region (Poland) In the Years 2001-2010, Macedonian Journal of Medical Sciences, 1857-5773.2014.0349. Badania Kliniczne Badania PASS/PAES/DUS Nieinterwencyjne Badania Obserwacyjne Obsługa Pharmacovigilance Konferencje, kongresy, szkolenia Ogłoszenia bieżące EUROPHARMA M. RACHTAN SP. Z O.O. jest beneficjentem dofinansowania w ramach Programu Operacyjnego Innowacyjna Gospodarka. Copyright © 2006–2015 EUROPHARMA